-
市場
-
產品
-
資訊
-
Moo社區
-
課堂
-
查看更多
-
功能介紹
-
費用費用透明,無最低余額限制
投資選擇、功能介紹、費用相關信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 淺色
Nova Mentis NM-1001 Psilocybin Compound Gets DEA Approval For Export, Here's What Happened
Nova Mentis NM-1001 Psilocybin Compound Gets DEA Approval For Export, Here's What Happened
Nova Mentis Life Science Corp. (OTCQB:NMLSF), also known as NOVA, a biotech company developing psilocybin-based therapeutics and complementary diagnostics for neuroinflammatory disorders, recently received the required controlled substances export approval from the U.S. Drug Enforcement Administration (DEA) for its proprietary psilocybin drug (NM-1001).
The company's goal is to diagnose and treat chronic conditions such as autism spectrum disorder (ASD) and Fragile X Syndrome (FXS) or Martin-Bell syndrome, one of the largest genetic causes of autism spectrum disorders. One interesting thing about the company is that, according to their statements, they are the first biotech to achieve orphan drug designation in both the United States and the European Union for the use of psilocybin in the treatment of Fragile X Syndrome (FXS).
With this permit, the company completed the successful import of its proprietary psilocybin drug (NM-1001) into Canada to the Toronto Institute of Pharmaceutical Technology (TIPT) labs, in order to formulate and manufacture psilocybin microdose capsules for a planned Phase 2A fragile X syndrome clinical study.
As NOVA president and CEO Will Rascan said, "This allows us to move forward with the formulation and final production of microdose capsules in preparation for our clinical trial application submission to Health Canada. We look forward to continuing to advance our research program to demonstrate the important role that microdose therapy may play in the treatment of autism spectrum disorder and FXS."
The company is conducting this study in different parts of the world. Earlier this year, NOVA announced that a very low microdose formulation of the Company's proprietary psilocybin drug (NM-1001) significantly modulated behavioral and cognitive defects, such as recognition memory, in a genetic model of FXS.
In the US, the enrollment for the study began in March and is still open to those interested.
Photo Courtesy of Hybrid on Unsplash.
Nova Mentis Life Science Corp. (OTCQB:NMLSF), also known as NOVA, a biotech company developing psilocybin-based therapeutics and complementary diagnostics for neuroinflammatory disorders, recently received the required controlled substances export approval from the U.S. Drug Enforcement Administration (DEA) for its proprietary psilocybin drug (NM-1001).
Nova Mentis生命科學公司(OTCQB:NMLSF),也被稱為Nova,一家開發基於裸蓋菇素的療法和針對神經炎性疾病的補充診斷的生物技術公司,最近獲得了所需的受控物質出口批准美國緝毒局(DEA)用於其專有裸蓋菇素藥物(NM-1001)。
The company's goal is to diagnose and treat chronic conditions such as autism spectrum disorder (ASD) and Fragile X Syndrome (FXS) or Martin-Bell syndrome, one of the largest genetic causes of autism spectrum disorders. One interesting thing about the company is that, according to their statements, they are the first biotech to achieve orphan drug designation in both the United States and the European Union for the use of psilocybin in the treatment of Fragile X Syndrome (FXS).
該公司的目標是診斷和治療慢性疾病,如自閉症譜系障礙(ASD)和脆性X綜合徵(FXS)或者馬丁-貝爾綜合徵,自閉症譜系障礙的最大遺傳原因之一。該公司有趣的一點是,根據他們的聲明,他們是第一個實現孤兒藥物名稱在美國和歐盟使用裸蓋菇素治療脆性X綜合徵(FXS)。
With this permit, the company completed the successful import of its proprietary psilocybin drug (NM-1001) into Canada to the Toronto Institute of Pharmaceutical Technology (TIPT) labs, in order to formulate and manufacture psilocybin microdose capsules for a planned Phase 2A fragile X syndrome clinical study.
憑藉這一許可,該公司成功地將其專有裸蓋菇素藥物(NM-1001)進口到加拿大多倫多製藥技術學院(Tipt)實驗室,以配方和製造裸蓋菇素微劑量膠囊,用於計劃中的2A期脆性X綜合徵臨牀研究。
As NOVA president and CEO Will Rascan said, "This allows us to move forward with the formulation and final production of microdose capsules in preparation for our clinical trial application submission to Health Canada. We look forward to continuing to advance our research program to demonstrate the important role that microdose therapy may play in the treatment of autism spectrum disorder and FXS."
ASNova總裁兼首席執行官威爾·拉斯坎這使我們能夠推進微劑量膠囊的配方和最終生產,為我們向加拿大衞生部提交臨牀試驗申請做準備。我們期待着繼續推進我們的研究計劃,以證明微劑量療法在自閉症譜系障礙和FXS治療中可能發揮的重要作用。
The company is conducting this study in different parts of the world. Earlier this year, NOVA announced that a very low microdose formulation of the Company's proprietary psilocybin drug (NM-1001) significantly modulated behavioral and cognitive defects, such as recognition memory, in a genetic model of FXS.
該公司正在世界各地進行這項研究。今年早些時候,Nova公司宣佈,該公司的裸蓋菇素專利藥物(NM-1001)的極低劑量配方顯著調節了FXS遺傳模型中的行為和認知缺陷,如識別記憶。
In the US, the enrollment for the study began in March and is still open to those interested.
在美國,這項研究從3月份開始招生,目前仍對感興趣的人開放。
Photo Courtesy of Hybrid on Unsplash.
照片由Unspash上的混合提供。
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國,moomoo上的投資產品和服務由Moomoo Financial Inc.提供,一家受美國證券交易委員會(SEC)監管的持牌主體。 Moomoo Financial Inc.是金融業監管局(FINRA)和證券投資者保護公司(SIPC)的成員。
在新加坡,moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供,該公司受新加坡金融管理局(MAS)監管(牌照號碼︰CMS101000) ,持有資本市場服務牌照 (CMS) ,持有財務顧問豁免(Exempt Financial Adviser)資質。本內容未經新加坡金融管理局的審查。
在澳大利亞,moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供,該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構(AFSL No. 224663)。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件,這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大,透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供,並受加拿大投資監管機構(CIRO)監管。
在馬來西亞,moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供,該公司受馬來西亞證券監督委員會(SC)監管(牌照號碼︰eCMSL/A0397/2024) ,持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.,Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
風險及免責聲明
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國,moomoo上的投資產品和服務由Moomoo Financial Inc.提供,一家受美國證券交易委員會(SEC)監管的持牌主體。 Moomoo Financial Inc.是金融業監管局(FINRA)和證券投資者保護公司(SIPC)的成員。
在新加坡,moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供,該公司受新加坡金融管理局(MAS)監管(牌照號碼︰CMS101000) ,持有資本市場服務牌照 (CMS) ,持有財務顧問豁免(Exempt Financial Adviser)資質。本內容未經新加坡金融管理局的審查。
在澳大利亞,moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供,該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構(AFSL No. 224663)。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件,這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大,透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供,並受加拿大投資監管機構(CIRO)監管。
在馬來西亞,moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供,該公司受馬來西亞證券監督委員會(SC)監管(牌照號碼︰eCMSL/A0397/2024) ,持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.,Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用瀏覽器的分享功能,分享給你的好友吧